Page 2 - Off Label Indication News Today

In Germany, drug shortages and supply problems have reached critical levels and are affecting the provision of care.

A new oral phosphodiesterase-4 (PDE4) inhibitor achieved impressive rates of complete or near-complete skin clearance in a phase 2 study that also found the drug was well tolerated.

Efforts to create a registry to track ketamine treatment has long been stymied. Amid an increase in off-label use, unregulated clinics, and relaxed DEA rules, has the field finally reached a tipping point?

Already approved for Dravet syndrome, fenfluramines approval for seizure control in Lennox-Gastaut syndrome was supported by data from a global, phase 3 clinical trial.

It was just as prevalent but with better outcomes as transcatheter mitral-valve repair emerged to take on high-risk cases. But more than just a shift in case mix seems responsible, researchers say.

Off-label use of acetylcholinesterase inhibitors and memantine is associated with better survival following hospitalization for patients with dementia with Lewy bodies (DLB).

Use of pimavanserin was associated with 35% lower mortality for patients with Parkinsons disease–related psychosis compared with atypical antipsychotics, a large new real-world analysis shows.

The agency continues to warn against using the Renuvion/J-Plasma system for skin contraction alone or in combination with liposuction, citing potentially life-threatening adverse events.

Frequently used off-label, the drug was not riskier than placebo, a new study found.

Adverse events that have been reported include second- and third-degree burns, infections, changes in skin color, and significant bleeding.